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BioPrivilege 
Lisa C. Ikemoto  
I. INTRODUCTION 
In Privilege Revealed: How Invisible Preference Undermines 
America,
1
 Stephanie Wildman and her co-conspirators, Margalynne 
Armstrong, Adrienne Davis, and Trina Grillo, exposed privilege as 
the unseen partner of domination and subordination. They 
demonstrated how implicit social norms and law intertwine to form 
systems of privilege. These systems operate as enforcers of the 
slightly more visible—in an iceberg kind of way—mechanisms of 
subordination, such as racism and patriarchy. Privilege Revealed 
emphasized the visible role of law but argued that silent normative 
preferences pervade our ways of knowing and living. The analysis 
invites all to participate in the project of making visible the substance 
and pervasiveness of privilege.
2
 
This Essay expands the privilege inquiry into the fields of 
biomedicine. BioPrivilege, as I define it, uses the characteristics of 
the dominant or privileged group to set the normative standards in 
health, define disease, and identify who does and does not comprise a 
risk group. I start with the normative body, used to train physicians, 
design research protocols, and define basic categories of health and 
disease. Until recently, that normative body was the white male. All 
others were defined by their deviance from this norm. This Essay 
 
  
Professor of Law, University of California, Davis School of Law. Special thanks to 
Irina Zamyatin, King Hall Class of 2013, who provided excellent research assistance. I also 
want to express my deep appreciation to Danielle Hart and Stephanie Wildman, for their spirit 
of collaboration in the pursuit of justice. 
 1. STEPHANIE M. WILDMAN, with Trina Grillo, Margalynne Armstrong & Adrienne 
Davis, PRIVILEGE REVEALED: HOW INVISIBLE PREFERENCE UNDERMINES AMERICA (1996). 
 2. Id. at 180 (“We cannot do this work alone; yet we must individually take 
responsibility for large parts of our own learning. We need to work both on ourselves and with 
each other . . . It is up to those of us with privilege to take our first steps toward dismantling this 
world of invisible preference and examining the privilege revealed.”). 
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uses this example and others to start a catalog of the forms and 
functions of BioPrivilege. The handful of examples I use show that, 
like privilege, BioPrivilege sometimes hides in plain sight. At other 
times, BioPrivilege is invisible until one remembers that BioPrivilege 
requires finding others deviant or problematic. BioPrivilege is the 
invisible enforcer of those categories. 
I have, in previous work, critiqued the privilege accorded to 
scientific knowledge.
3
 I challenged as often misplaced the 
presumption that scientific knowledge is more salient and more 
reliable than, for example, experiential knowledge. Here, I use the 
deference given to science as a starting point. The status accorded 
science magnifies BioPrivilege. I focus, however, on the content of 
biomedical knowledge. In other words, I explore, in a biomedical 
scientific context, Wildman & Co.’s premise that privilege pervades 
our ways of knowing. 
Part II of this Essay provides a more detailed definition of 
BioPrivilege and examines the role of the status accorded science in 
magnifying BioPrivilege. Part III parses some of the ways in which 
BioPrivilege functions. More specifically, this analysis focuses on 
how biomedical knowledge is formed around and enforces 
subordination. Part IV looks to projects that have achieved some 
success in revealing and challenging BioPrivilege. Those initiatives 
suggest both next steps and potential pitfalls in working toward 
BioEquality. Part V concludes with a summary of the issues we face 
in the future. 
II. BIOPRIVILEGE BASICS 
BioPrivilege is simply a subset of privilege. The discussion that 
follows describes the parameters of that subset. Two points undergird 
the concept of BioPrivilege. First, biomedical knowledge includes 
normative content. Second, biomedicine draws much of its power 
from the status of science, and as a result, science has norm-making 
power. 
 
 3. Lisa C. Ikemoto, The Code of Perfect Pregnancy: At the Intersection of the Ideology 
of Motherhood, the Practice of Defaulting to Science, and the Interventionist Mindset of Law, 
53 OHIO ST. L.J. 1205, 1286–90 (1992). 
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A. BioPrivilege Defined 
Privilege uses the characteristics of the privileged group as the 
affirming societal norm.
4
 That is, the characteristics of those on the 
dominant side of power
5
 define “normal,” “meritorious,” 
“reasonable,” and other standards used to justify particular conferrals 
of benefit and advantage. Thus camouflaged, the systemic nature of 
those conferrals remains invisible until deliberately exposed. Peggy 
McIntosh’s list of quotidian examples in White Privilege: Unpacking 
the Invisible Backpack
6
 illustrates that point. The very ordinariness of 
the examples gives them punch.  
Consider Professor McIntosh’s Example 24.7 “I can be sure that if 
I need legal or medical help, my race will not work against me.”8 
Professor McIntosh may have been acknowledging the ways in which 
race mediates access to health care. In general, whites are more likely 
to have health insurance and therefore, access to health care.
9
 She 
may have been highlighting the ways in which a patient’s race affects 
the decisions the provider makes in treating patients. For example, 
studies show that providers are more likely to treat disease 
aggressively in white males and least likely to treat disease 
aggressively in Black women.
10
 In many ways, race allocates access 
to and quality of care unequally.
11
 Broadly speaking, Example 24 
implicates structural racism that constrains access for some but not 
others as well as cultural racism that intervenes in the provider-
patient relationship. In effect, these systems confer advantage and 
 
 4. WILDMAN, supra note 1, at 13. 
 5. Id. at 29. 
 6. Peggy McIntosh, White Privilege: Unpacking the Invisible Knapsack, PEACE & 
FREEDOM MAG., July–Aug. 1989, at 10–12. 
 7. Id. at 11. 
 8. Id. 
 9. KAISER COMM’N ON MEDICAID & THE UNINSURED, THE UNINSURED: A PRIMER 6 
(2012), available at http://www.kff.org/uninsured/upload/7451-08.pdf.  
 10. See Kevin A. Schulman et al., The Effect of Race and Sex on Physicians’ 
Recommendations for Cardiac Catheterization, 340 NEW ENG. J. MED. 618, 624 (1999). Tables 
4 and 5 and the accompanying text indicate that physicians refer women, particularly Black 
women, for cardiac catheterization far less frequently than men. 
 11. See generally UNEQUAL TREATMENT: CONFRONTING RACIAL AND ETHNIC 
DISPARITIES IN HEALTH CARE (Brian D. Smedley et al. eds., 2003).  
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disadvantage among patients by race.
12
 What Professor McIntosh’s 
example shows is how the advantage rests on and is exploitative of 
systemic disadvantage.  
I want to use the point about medical help in Example 24 to 
illustrate what I mean by BioPrivilege. BioPrivilege operates on the 
microlevel of biomedical science. BioPrivilege is formed by the 
incorporation of privilege into biomedical knowledge itself. As noted 
in Part I, until fairly recently, the normative body in medicine and 
biomedical research was white and male. A study of anatomy 
textbooks found that in the non-reproductive illustrations, the male 
body was represented at a substantially higher rate than the female 
body.
13
 More specifically, the study showed that “women constituted 
an average of 11.1% of nonreproductive anatomy illustrations and an 
average of 8.8% of nonreproductive physical diagnosis illustrations, 
while men were drawn in 43.1% and 23.7% of the respective 
illustrations.”14 The finding suggests gender bias and indicates that 
medical students acquire “an incomplete knowledge of normal female 
anatomy.”15 Incomplete knowledge may undercut quality of care. 
Privilege, as Wildman & Co. show, runs along many axes. 
BioPrivilege uses the characteristics of the privileged group to 
define the medical norm, the standard of health, even the symptoms 
of disease, in a way that confers benefit or advantage on members of 
the privileged group. Use of the male body as the typical human 
reinforces male privilege.
16
 In Donna Haraway’s words, “bodies, 
 
 12. See Kristine Martin-McDonald & Alexandra McCarthy, ‘Marking’ the White Terrain 
in Indigenous Health Research: Literature Review, 61 J. ADV. NURS. 126, 129 (2007) (“The 
socio-cultural ‘terrain’ of whiteness is constituted by three linked dimensions: a location of 
structural advantage; a white standpoint or worldview of self, society and other and a set of 
cultural practices that are usually ‘unmarked’ and unnamed.”) (citing RUTH FRANKENBERG, 
WHITE WOMEN, RACE MATTERS: THE SOCIAL CONSTRUCTION OF WHITENESS (1993) and B. 
Siegal, The Compliance and Adherence Process in the Transplant Patient: Professional 
Responsibility, 24 DIALYSIS & TRANSPLANTATION 189 (1995)). 
 13. Kathleen D. Mendelsohn, Linda Z. Neiman, Krista Isaacs, Sophia Lee & Sandra P. 
Levison, Sex and Gender Bias in Anatomy and Physical Diagnosis Text Illustrations, 272 
JAMA 1267 (1994); see also Sandra P. Levison et al., Letter to the Editor, In Reply, 273 JAMA 
1257 (1995). 
 14. Mendelsohn et al., supra note 13, at 1269. 
 15. Id. 
 16. Id. (“Readers may assume that what is depicted in the text is normal and what is 
absent is abnormal or irrelevant.”). 
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then, are not born; they are made.”17 As a result, males who need 
medical help are less likely than females to find that their sex works 
against them. 
BioPrivilege operates under cover of dominant group 
characteristics. This cover enables BioPrivilege to hide in plain sight. 
The pervasiveness of the normative male body made the 
predominance of male body representations in textbooks seem 
appropriate and neutral. The same logic may have undergirded the 
use of males and only males in clinical trials.
18
 Until the 1990s, 
clinical trials to study the mechanisms of disease, as well as the 
efficacy and safety of therapies, were run using only male bodies. 
Biomedical knowledge acquired by clinical trial produced knowledge 
based on male bodies. As a result, there is more data and 
understanding of men’s health, of diseases and other conditions that 
affect men (and often women, as well), and more accurate knowledge 
about treating men than women.
19
  
Efforts to change these practices highlighted the causal link 
between the normative white male body and lower quality health care 
for women and persons of color.
20
 They also revealed the effects of 
BioPrivilege. Health care disparities, resulting in part from use of a 
singular normative body, persist. But efforts to address the gender 
and race gaps in biomedical knowledge have started to improve the 
 
 17. DONNA J. HARAWAY, SIMIANS, CYBORGS, AND WOMEN: THE REINVENTION OF 
NATURE 208 (1991). 
 18. For another plausible explanation, see Nancy Krieger & Elizabeth Fee, Man-Made 
Medicine and Women’s Health: The Biopolitics of Sex/Gender and Race/Ethnicity, in MAN-
MADE MEDICINE: WOMEN’S HEALTH, PUBLIC POLICY, AND REFORM 15, 21 (Kary L. Moss ed., 
1996) (“In fact, by the time that researchers began to standardize methods for clinical and 
epidemiological research, notions of difference were so firmly embedded that whites and 
nonwhites, women and men, were rarely studied together. Moreover, most researchers and 
physicians were interested only in the health status of whites, and, in the case of women, only in 
their reproductive health.”). 
 19. See generally MAN-MADE MEDICINE, supra note 18; R. Alta Charo, Protecting Us to 
Death: Women, Pregnancy, and Clinical Research Trials, 38 ST. LOUIS U. L.J. 135 (1993–94); 
Karen H. Rothenberg, Gender Matters: Implications for Clinical Research and Women’s 
Health Care, 32 HOUS. L. REV. 1201 (1995–96). 
 20. See generally U.S. DEP’T OF HEALTH & HUMAN SERVS., REPORT OF THE 
SECRETARY’S TASK FORCE ON BLACK AND MINORITY HEALTH 12 (1985) (“Many professionals 
and lay persons, both minority and nonminority, do not know that heart disease may be as 
common in Black men as in nonminority men or that Black women die from coronary disease 
at a higher rate than nonminority women.”). 
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quality of care for women and some racial and ethnic populations. 
Adrienne Davis’s insight that inequality does not run on the single 
engine of subordination but on a hydra-headed machine of 
subordination, domination, and privilege
21
 helps explain the 
persistence of norms and practices that give rise to health care 
inequalities. Improvements in quality of care provide evidence that 
revealing BioPrivilege and acting to change the structures and norms 
that support it can reduce inequalities in health care that give rise to 
health care disparities.
22
 
B. Science as Privileged Knowledge 
BioPrivilege draws much of its power from the status that science 
holds. Science as knowledge carries great weight in many contexts 
and is privileged over other forms of knowledge and other types of 
enterprise.
23
 Science, then, magnifies the influence of norms and 
standards used in medicine, health, and biomedical research.  
1. Privileged Knowledge 
Science as a form of knowledge receives deferential treatment.
24
 
Other forms of knowledge are respected in discrete contexts. Often, 
however, we regard other forms of knowledge either as more trivial 
or less reliable than science. Compare the way we value scientific 
knowledge production with the way we value cultural knowledge 
production. The National Institutes of Health (NIH) receives 
substantially greater funding than the National Endowment for the 
Arts (NEA).
25
 Both produce knowledge for the greater social good.
26
 
 
 21. WILDMAN, supra note 1, at 19–20; see also generally, e.g., Martin-McDonald & 
McCarthy, supra note 12. 
 22. WILDMAN, supra note 1, at 24. 
 23. STANLEY ARONOWITZ, SCIENCE AS POWER: DISCOURSE AND IDEOLOGY IN MODERN 
SOCIETY 8 (1988) (“In the knowledge hierarchies of postfeudal societies, modern scientific 
rationality is the privileged discourse, and all others are relegated to the margins.”). 
 24. Science’s status as privileged knowledge has been under attack for the past forty 
years. Id. at 11. 
 25. For fiscal year 2012, Congress appropriated $32 billion for the NIH. NAT’L INSTS. OF 
HEALTH, OVERVIEW BY INSTITUTE (2011), available at http://www.nih.gov/about/director/ 
budgetrequest/NIH_BIB_020911.pdf. For the same fiscal year, the NEA received $146 
million—$8.7 million less than the Endowment’s total budget for 2011. National Endowment 
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Both receive only a portion of the total funding provided to 
biomedical science and art in the United States. But both are 
emblematic of our disparate national commitments to science and art. 
The funding gap between the NIH and the NEA provides a rough 
measure of the relative weight society places on the two endeavors.  
Consider, also, our responses to contests between scientific and 
experiential knowledge. Science does not always prevail. But 
consider the distinctions deployed in contest. Fact versus belief. Data 
versus anecdote. Rational versus emotional. Testable versus 
unreliable.
27
 In science, law, and public policy discourse, “data,” 
“rational,” and “testable” are positive terms. They endorse. Not 
coincidentally, they describe what we mean by “science.” 
“Anecdotal” and “emotional” are not necessarily negative terms, but 
science, law, and public policy discourse use those terms as 
synonyms for “weak.” In nearly every context, “unreliable” carries 
negative meaning.  
We defer to science for several reasons, all of which reflect some 
version of Western secular rationalism.
28
 First, we value scientific 
knowledge on the premise that it is testable and ideologically neutral. 
We also highly value the training and supposedly resulting expertise 
of those who work in science. On those grounds, we presume that 
science is more reliable and credible than other forms of knowledge. 
Third, we presume scientific enterprise will produce benefits that will 
accrue to many, if not all. We regard those benefits—products and 
knowledge—as social goods. We regard the enterprise as socially 
 
for the Arts Appropriations History, NAT’L ENDOWMENT FOR THE ARTS, http://www.arts.gov/ 
about/Budget/AppropriationsHistory.html (last visited Feb. 7, 2013); see also Jacqueline 
Trescott, In 2012 Federal Budget, NEA is Cut and Smithsonian Gets a Raise, WASH. POST 
(Dec. 20, 2011, 12:14 PM), http://www.washingtonpost.com/blogs/arts-post/post/in-2012-feder 
al-budget-nea-is-cut-and-smithsonian-gets-a-raise/2011/12/20/gIQAXy8D7O_blog.html. 
 26. “NIH’s mission is to seek fundamental knowledge about the nature and behavior of 
living systems and the application of that knowledge to enhance health, lengthen life, and 
reduce the burdens of illness and disability.” Mission, NAT’L INSTS. OF HEALTH, 
http://www.nih.gov/about/mission.htm (last visited Feb. 7, 2013). The mission of the NEA is 
“to advance artistic excellence, creativity, and innovation for the benefit of individuals and 
communities.” NAT’L ENDOWMENT FOR THE ARTS, STRATEGIC PLAN (2010), available at 
http://www.nea.gov/about/Budget/NEAStrategicPlan2012-2016.pdf. 
 27. See generally DONNA J. HARAWAY, MODEST_WITNESS@SECOND_MILLENIUM 
.FEMALEMAN©_MEETS_ONCOMOUSE™ 277 (1997). 
 28. See generally ARONOWITZ, supra note 23, at 9.  
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valuable.
29
 In addition, we tend to equate scientific innovation with 
progress.
30
 This last equation serves two functions: it justifies the 
privilege accorded science and buffers science from serious challenge 
as a valuable enterprise. 
2. Norm-Making Power 
Because of the deference given to science, scientific knowledge 
has norm-making power. Social norms incorporate science in at least 
four ways. Scientific knowledge is sometimes translated directly into 
legal rules. Changes in social norms follow. For example, social 
practices used as health and safety precautions often arise in response 
to public health education efforts that in turn were based on public 
health science. Science demonstrated serious health risks of social 
activities such as drinking and smoking. Both legal rules and social 
norms for acceptable alcohol and tobacco use have changed 
substantially, in part, because so many deferred to the data showing 
significant risk. 
Science does not always direct the norm. Sometimes, a norm or 
even a normative change draws on science to explain the norm. In his 
historiography of gender, Thomas Lacquer examines the switch from 
a one sex model to an opposite sex model for understanding the 
human body.
31
 He theorizes that the switch was not driven by new 
biological knowledge. Rather, broad changes in epistemology and 
politics initiated adoption of the opposite sex model, which then drew 
on biology to explain the opposite sex model as preferable.
32
 
Science is also used to reinvigorate norms premised on outmoded 
explanations. For example, the concept of biological race was used to 
 
 29. See generally Moore v. Regents of the Univ. of Cal., 793 P.2d 479, 487, 495 (1990) 
(discussing “medical research of importance to all of society” as “implicat[ing] policy 
concerns” and implying a need to avoid compromising the exchange of scientific materials for 
experimental purposes with lawsuits); Wash. Univ. v. Catalona, 490 F.3d 667, 674 (8th Cir. 
2007) (observing, as an integral part of the holding that biological samples belonged to the 
University and not to a particular researcher, that donors of the samples intended their donations 
as “‘a free and generous gift of [biological materials] to research that may benefit society’”). 
 30. Ikemoto, supra note 3, at 1286. 
 31. THOMAS LAQUEUR, MAKING SEX: BODY AND GENDER FROM THE GREEKS TO FREUD 
(1990).  
 32. Id. at 10–12. 
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justify racial subordination and claims of white supremacy as well as 
practices—including slavery, eugenics, and segregation—premised 
on those systems.
33
 Biological race fell into disrepute as respected 
scientists challenged the “science” in eugenic science and the world 
acknowledged the role that biological race played in Nazi ideology.
34
 
Since the 1940s, science has declared biological race dead or near 
dead more than once. Notably, at a White House press conference 
convened to announce the success of the Human Genome Project, 
President Bill Clinton stated, “I believe one of the great truths to 
emerge from this triumphant expedition inside the human genome is 
that in genetic terms all human beings, regardless of race, are more 
than 99.9 percent the same.”35 And yet, genetics has become the most 
significant new vehicle for explaining racial difference.
36
 
Sometimes, science-like cover is given to norms, often 
controversial norms, as apparent justification. The claim of genetic 
race or the new biological race is methodologically unsound.
37
 For 
the moment, however, genetic science is a dominant explanatory 
paradigm. It holds such sway that claims made as genetic science 
seem logical and entitled to deference. Consider a more contested 
example. In the past few years, abortion opponents have framed their 
arguments in medicalized terms.
38
 Some claim that women who 
 
 33. See generally Stephen Jay Gould, American Polygeny and Craniometry Before 
Darwin: Blacks and Indians as Separate, Inferior Species, in THE “RACIAL” ECONOMY OF 
SCIENCE: TOWARD A DEMOCRATIC FUTURE 84, 111–14 (Sandra Harding ed., 1993); DOROTHY 
ROBERTS, FATAL INVENTION: HOW SCIENCE, POLITICS, AND BIG BUSINESS RE-CREATE RACE 
IN THE TWENTY-FIRST CENTURY 35–43 (2011). 
 34. ROBERTS, supra note 33, at 43. 
 35. Remarks Made by the President, Prime Minister Tony Blair of England (via satellite), 
Dr. Francis Collins, Director of the National Human Genome Research Institute, and Dr. 
Craig Venter, President and Chief Scientific Officer, Celera Genomics Corporation, on the 
Completion of the First Survey of the Entire Human Genome Project, THE WHITE HOUSE—
OFFICE OF THE PRESS SECRETARY (June 26, 2000), available at http://www.genome.gov/ 
10001356. 
 36. See generally ROBERTS, supra note 33; MICHAEL J. MONTOYA, MAKING THE 
MEXICAN DIABETIC: RACE, SCIENCE, AND THE GENETICS OF INEQUALITY (2011).  
 37. See Deborah A. Bolnick, Individual Ancestry Inference and the Reification of Race as 
a Biological Phenomenon, in REVISITING RACE IN A GENOMIC AGE 70 (Barbara A. Koenig et 
al. eds., 2008). 
 38. See Reva B. Siegel, The Right’s Reasons: Constitutional Conflict and the Spread of 
Woman-Protective Antiabortion Argument, 57 DUKE L.J. 1641 (2008).  
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obtain abortions have an increased risk of breast cancer,
39
 that women 
who obtain abortions risk their mental health.
40
 Actual scientific 
evidence weighs against both claims.
41
 Both claims have been 
contested in public discourse in ways that genetic race has not. And 
yet, in his opinion for the Court, Justice Kennedy used the risk of 
“regret” as part of the justification for upholding the law at issue in 
Gonzales v. Carhart, even as he acknowledged that “no reliable 
data”42 backed the claim. Characterizing a claim in medical terms 
indicates the influence that science has in public discourse and in the 
law.  
The irony is that science is valued in large part because we regard 
it as apolitical. At the same time, the distinctions drawn to privilege 
science are contested and those contestations are political in nature. 
The power to draw those distinctions, to define what counts as 
science and not science, is what is at stake.
43
 
C. Privilege and Biomedicine 
BioPrivilege draws some or much of its power from the status of 
science in general. Yet, the field of biomedical science seems to be 
particularly influential. Broader political and economic forces 
probably explain the particular influence of biomedical science at this 
time.
44
 It is also likely that biomedicine’s direct applicability, or at 
least its potential for applicability to the individual human makes 
biomedical science seem more relevant and more interesting. We 
 
 39. Id. at 1653. 
 40. Id. 
 41. Id. at n.44. 
 42. Gonzales v. Carhart, 550 U.S. 124, 159 (2007). 
 43. See generally HARAWAY, supra note 27, at 89 (“My goal is to help put the boundary 
between the technical and the political back into permanent question as part of the obligation of 
building situated knowledges inside the materialized narrative fields of technoscience.”). 
 44. See MELINDA COOPER, LIFE AS SURPLUS: BIOTECHNOLOGY & CAPITALISM IN THE 
NEOLIBERAL ERA 3 (2008) (“. . . the biotech era poses challenging questions about the 
interrelationship between economic and biological growth, resurrecting in often unexpected 
ways the questions that accompanied the birth of the modern political economy . . .”). 
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each have a stake in biomedicine’s potential and its power.45 
BioPrivilege, then, is worth examining as a particular political force. 
III. BIOPRIVILEGE AS THE INVISIBLE ENFORCER 
A. BioPrivilege as Club Doorman 
BioPrivilege is the invisible enforcer of norms and practices
46
 
used to perpetuate exclusion or subordination in the name of 
medicine and science. Consider the effect of the normative male body 
on non-normative bodies. Bodies that do not fit the standard might be 
understood as nonstandard in a positive way. We laud atypical height 
and strength. In some communities, persons with conditions we 
consider to be “disabilities” are not regarded as problematic, and may 
even been seen as blessings.
47
 But BioPrivilege functions more like a 
club doorman, the guy who controls access to nightclubs. For those 
the doorman admits, both the admission and the barring of the 
objectionable affirm the club’s merit and the patron’s sense of 
belonging. Privilege, then, requires situating the nonstandard as 
objectionable. Thus, while “it was assumed that males, particularly 
Caucasian males, provided the ‘norm’ or ‘standard,’ . . . there was a 
tendency to view females as being ‘deviant or problematic, even in 
studying diseases that affect both sexes.’”48  
 
 45. See generally Adele E. Clarke, Laura Mamo, Jennifer Ruth Fosket, Jennifer R. 
Fishman & Janet Shim, Biomedicalization, in BIOMEDICALIZATION: TECHNOSCIENCE, HEALTH 
& ILLNESS IN THE U.S. 4–6 (Adele E. Clarke et al. eds., 2010). 
 46. WILDMAN, supra note 1, at 7–24, 27 
 47. See, e.g., KAJA FINKLER, EXPERIENCING THE NEW GENETICS: FAMILY AND KINSHIP 
ON THE MEDICAL FRONTIER 177–78 (2000); ANNE FADIMAN, THE SPIRIT CATCHES YOU AND 
YOU FALL DOWN: A HMONG CHILD, HER AMERICAN DOCTORS, AND THE COLLISION OF TWO 
CULTURES (1997). 
 48. 1 INST. OF MED., WOMEN AND HEALTH RESEARCH: ETHICAL AND LEGAL ISSUES OF 
INCLUDING WOMEN IN CLINICAL STUDIES 8 (A.C. Mastroianni et al. eds., 1994) (“Two forms 
of unconscious gender bias have particular relevance for the design and conduct of clinical 
studies: male bias (observer error caused by adopting a male perspective and habit of thought) 
and the male norm (the tendency to use males as the standard and to see females as deviant or 
problematic, even in studying diseases that affect both sexes). Both have been thought to 
contribute to a predominant focus on men's health problems and on men as research 
participants.”). 
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As noted above, until the 1990s researchers relied on this view to 
exclude white women
49
 and women and men of color from clinical 
trials. According to “rational” design principles, homogeneity of the 
study population strengthened study design and prevented variables, 
such as hormonal cycles, from becoming confounding factors.
50
 
White males, as the normative humans, were the study population for 
decades. During that period, drugs, devices, procedures, and 
biomedical knowledge were produced in a way that made the 
products and knowledge less likely to help and more likely to harm 
members of the excluded populations than those of the normative 
population.
51
 The invisibility of the normative white male body 
removed it as an explanation for this phenomenon. While the 
normative body remained unseen, the ascribed deviance of the non-
normative patients explained the lower rates of efficacy and the 
higher rates of harm. 
Characterizing female bodies and, in fact, all bodies not white and 
male as deviant and problematic expressed social bias in medical 
terms. That bias became the justification for exclusion and the 
explanation for exclusion’s effect. The invisibility of privilege made 
the circularity of that logic difficult to see.  
 
 49. INST. OF MED., EXPLORING THE BIOLOGICAL CONTRIBUTIONS TO HUMAN HEALTH: 
DOES SEX MATTER 24 (Thereza M. Wizemann & Mary-Lou Pardue eds., 2001) (“Although 
none of these provisions excluded specific subpopulations from clinical research, the policies 
stated that subjects who were vulnerable because of physical, mental, or social circumstances 
must not be exploited. Hence, few women were included, as pregnant women and their fetuses 
were grouped into the category of “vulnerable populations.”). 
 50. Id. at 25 (“Scientifically, women were excluded as clinical research participants 
because (1) there was a general belief among clinical researchers that men and women will not 
differ significantly in response to treatment in most situations, and (2) the inclusion of women 
introduces additional variables (in the form of hormonal cycles) and decreases the homogeneity 
of the study population. Ironically, even as it was acknowledged that the female hormonal cycle 
is a significant confounding variable and test substances might respond unpredictably to 
hormonal fluctuations, it was nonetheless widely believed that men and women were similar 
enough that it was acceptable to then treat women with therapies developed solely on the basis 
of the results of studies performed with men as research subjects.” (internal citations omitted)). 
 51. See generally id.; 1 U.S. PUB. HEALTH SERV., REPORT OF THE PUB. HEALTH SERV. 
TASK FORCE ON WOMEN’S HEALTH ISSUES 73–104 (1985), available at http://www.ncbi.nlm 
.nih.gov/pmc/articles/PMC1424718/pdf/pubhealthrep00101-0075.pdf. 
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B. BioImmunity 
In biomedical terms, the immune system functions by 
differentiating between self and other and then protecting self against 
the other. Biomedicine often performs a similar function.
52
 The 
science of disease etiology incorporates social concepts of self and 
other that, in effect, maintain those boundaries. BioPrivilege 
performs important work in holding the boundaries, often with 
negative health consequences for those outside the resulting bio-
normative line. 
1. Building BioPrivilege into Disease Models 
In some cases, etiological science imbues disease with the social 
identity of those deemed objectionable. Disease etiology may locate 
causation or origin within a population itself. Etiological hypotheses 
and explanations that incorporate characteristics of outsider identities 
maintain boundaries between the diseased other and the normative 
self. Disease models that focus on the other help maintain the 
invisibility of BioPrivilege. They simultaneously and quietly position 
the privileged group as normally healthy and disease-resistant.  
Not surprisingly, the history of scientific racism provides some 
interesting examples. Many are familiar with the early nineteenth-
century development of comparative anatomy to justify racial 
hierarchy. This work signaled a shift in scientific focus from external 
features to the body’s internal features and functions.53 Theories 
about the origins and causes of disease in different populations soon 
followed. During the nineteenth century, before the advent of germ 
theory, several explanations for tuberculosis emerged. Some 
proponents of scientific racism insisted that tuberculosis in whites 
was not the same disease as tuberculosis in Blacks. “Negro 
 
 52. See HARAWAY, supra note 17, at 204–05 (“. . . the immune system is a map drawn to 
guide recognition and misrecognition of self and other in the dialectics of Western 
biopolitics.”). 
 53. See generally STEPHEN JAY GOULD, THE MISMEASURE OF MAN (1981); see also 
WILLIAM A. TUCKER, THE SCIENCE AND POLITICS OF RACIAL RESEARCH 12–13 (1994). 
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consumption,” then, was particular to Blacks.54 Those who embraced 
this theory believed that Blacks were predisposed to illness and that 
whites were not.
55
 “White consumption” afflicted only whites. In this 
view, white consumption did not evidence weakness and may have 
even suggested physiological superiority. 
Some diseases are specifically associated with the privileged 
group. For example, heart disease, including myocardial infarction, 
had higher incidence rates among men. As a result, the disease 
enjoyed the privilege of its at-risk population: higher risk rates among 
men produced close attention to and substantial funding for the study 
and prevention of heart disease. Even now, when we know that rates 
of heart disease as a cause of death differ little by sex,
56
 “research 
funding for coronary heart disease in men is far greater than for 
women.”57 Thanks to that research and to public health education, 
many know that common symptoms of myocardial infarction include 
tight, often intermittent, chest pain, shortness of breath, and pain in 
other upper body parts, including the right arm. Yet, less than ten 
years ago, researchers acknowledged that “[l]ittle is known about 
early warning or prodromal [coronary heart disease] symptoms in 
women.”58 Very recently, research has shown that women may 
experience or report different symptoms, and women are less likely 
to experience the chest pain that has been considered emblematic of 
heart attack onset.
59
 “Instead, they may experience shortness of 
breath, pressure or pain in the lower chest or upper abdomen, 
 
 54. SAMUEL KELTON ROBERTS, JR., INFECTIOUS FEAR: POLITICS, DISEASE, AND THE 
HEALTH EFFECTS OF SEGREGATION 44 (2009). 
 55. See generally id. 
 56. See Melonie Heron, U.S. Ctrs. for Disease Control & Prevention, Deaths: Leading 
Causes for 2009, 61 NAT’L VITAL STAT. REP. 7, 5–9 (2012), available at http://www.cdc.gov/ 
nchs/data/nvsr/nvsr61/nvsr61_07.pdf. 
 57. Anita Holcroft, Gender Bias in Research: How Does It Affect Evidence Based 
Medicine?, 100 J. ROYAL SOC’Y MED. 2 (2007). 
 58. Jean C. McSweeney et al., Women’s Early Warning Symptoms of Acute Myocardial 
Infarction, 108 CIRCULATION 2619 (2003). 
 59. Id. at 2622; see also John G. Canto et al., Association of Age and Sex with Myocardial 
Infarction Symptom Presentation and In-Hospital Mortality, 307 JAMA 813, 816 (2012). Some 
findings about gender differences in reported chest pain have been inconsistent, but most 
research indicates that women experience symptoms not previously recognized as myocardial 
infarction symptoms. See Johanna Berg et al., Symptoms of a First Acute Myocardial Infarction 
in Women and Men, 6 GENDER MED. 454, 455 (2009).  
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dizziness, lightheadedness or fainting, upper back pressure or 
extreme fatigue.”60 Since patients who do not report chest pain are 
less likely to be correctly diagnosed and receive aggressive treatment 
for myocardial infarction, heart disease’s normative model 
disproportionately harms female heart attack victims.
61
  
Heart disease has been the leading cause of death for both men 
and women.
62
 But the disease model was built on the experience of 
males. Privilege played at least two roles. Privilege helped prioritize 
heart disease on the biomedical research and public health agendas. 
In addition, building a disease model for the default normative body 
enabled the model to be universalized without question. The 
normative disease model, like the body, set diagnosis and treatment 
standards for all.  
In some cases, the social identity that informs the disease model 
may be so visible that it precludes application to those who report the 
same symptoms but do not match the model’s social profile. For 
example, breast cancer has a higher incidence rate in white women in 
the United States. This had at least two effects on non-white women. 
Women of color reporting symptoms that aligned with the disease 
model were less likely to be diagnosed in a timely fashion. In the 
United States, many doctors relied on breast cancer incidence rates 
collected in Asia to diagnose Asian American women. But breast 
cancer rates among women in Asia have been significantly lower 
than among all women, including Asian women—in the United 
States. So an Asian American woman reporting a lump to her doctor 
in the United States was less likely to be tested for breast cancer on 
the assumption that Asian women do not get breast cancer. While 
breast cancer rates for Asian American women are lower than for 
white women in the United States, Asian American women are at 
significant risk for breast cancer. Similarly, federally required data 
collection by race and ethnicity revealed not only that women of 
color have significant risks of breast cancer, but also that Black 
 
 60. Heart Attack Symptoms in Women, AM. HEART ASS’N (Feb. 6, 2013), 
http://www.heart.org/HEARTORG/Conditions/HeartAttack/WarningSignsofaHeartAttack/Hear
t-Attack-Symptoms-in-Women_UCM_436448_Article.jsp (last visited Feb. 9, 2013); see also 
McSweeney et al., supra note 58. 
 61. Canto et al., supra note 59, at 816. 
 62. Heron, supra note 56. 
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women are more likely than white women to die from breast cancer. 
This came as a shock to the medical and research communities. In the 
case of breast cancer, the disease and the identity of its primary risk 
group so closely intertwined that the most important symptom 
became “white woman.” When a white woman reported a breast 
lump, her experience echoed that of Professor McIntosh. Her race did 
not work against her.
63
 The same could not be said for women of 
color. 
2. The Persistence of BioPrivilege 
Disease models that maintain political boundaries persist, even in 
the face of additional knowledge that counters the model’s social 
content. Typically, a disease model adapts to the new knowledge. 
Sometimes, the model simply shifts the political boundaries to 
encompass the new knowledge. But sometimes, the model 
accommodates the new knowledge without shifting the BioPrivilege 
boundary. Thus, the model evolves, allowing its subordinating and 
privileging functions to persist. 
Germ theory emerged in the late nineteenth century as an 
explanation for infectious disease. Soon after, in 1882, Robert Koch 
identified the bacteria that caused tuberculosis. Acceptance of the 
tubercle bacillus as the causal agent of tuberculosis proved that 
tuberculosis was infectious. It should also have proved that 
tuberculosis was race-neutral. Yet, racialized explanations for the 
disease and its effects persisted. For example, some continued to 
posit race-specific predisposition to explain higher mortality rates 
among African Americans.
64
 Others blamed emancipation—“the 
wages of urban freedom” that “possibly signaled the race’s 
degeneration or even extinction.”65 Thus, post-Civil War 
interpretations of tuberculosis contained anti-emancipation ideology. 
The most well-known example of the evolution of disease models 
is the story of epidemiological efforts to address Acquired 
Immunodeficiency Syndrome, or AIDS. The CDC reported the 
 
 63. McIntosh, supra note 6, at 11. 
 64. ROBERTS, supra note 54, at 47. 
 65. Id. at 46. For other explanations, see id. at 47–63. 
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outbreak among young gay men with pneumocystis carinii 
pneumonia and Kaposi’s sarcoma in 1981. The men were later found 
to have died from complications of full-blown AIDS. At that time, 
reports framed the disease wholly in terms of its victims’ sexual 
orientation. During this period, the name GRID or Gay-Related 
Immune Disease attached. Researchers found the link between the 
disease phenomena and the gay community so compelling that they 
“at first ignored cases of AIDS that did not fit the gay plague 
model.”66 Women, Haitians, and intravenous drug users who did not 
fit the profile, who were not gay men, were either placed in a 
different diagnostic category, or researchers assumed that males with 
AIDS who denied male with male sex had lied about their sexual 
history.
67
 
At that time, the dominant paradigm for most disease research was 
that of a universal causal agent, such as bacteria or virus.
68
 Yet, the 
prevailing view of GRID posited a multi-causal explanation centered 
on a particular sexual and social identity—gay men and their ascribed 
lifestyle.
69
 In mid-1982, the number of patients who were not gay 
men and yet had AIDS-related complications increased, making virus 
theory difficult to ignore.
70
 The prevailing response in the biomedical 
community was to expand the social boundaries of the disease, even 
as it began to accept the Human Immunodeficiency Virus (HIV) as a 
unicausal agent. Epidemiologists then focused on the “4-H risk 
groups.” As a result, homosexuals, Haitians, hemophiliacs, and 
heroin addicts became part of the disease profile.
71
  
Biomedicine now defines tuberculosis and HIV/AIDS as diseases 
that may infect anyone by transmission of bacillus and retrovirus, 
respectively. Treatment of HIV, negotiated in part by AIDS activists, 
 
 66. Elizabeth Fee & Nancy Krieger, Understanding AIDS: Historical Interpretations and 
the Limits of Biomedical Individualism, 83 AM. J. PUB. HEALTH 1477, 1478 (1993). 
 67. Id.  
 68. STEVEN EPSTEIN, IMPURE SCIENCE: AIDS, ACTIVISM, AND THE POLITICS OF 
KNOWLEDGE 57 (1996). 
 69. Id. 
 70. Id. at 56. But those with HIV were also sub-categorized by the manner in which their 
T cells “capitulated” to the virus in ways that perpetuated gender and lifestyle segregation. See 
CATHERINE WALDBY, AIDS AND THE BODY POLITIC: BIOMEDICINE AND SEXUAL DIFFERENCE 
67 (1996). 
 71. Fee & Krieger, supra note 66, at 1478. 
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has transformed HIV infection from a terminal diagnosis to a chronic 
condition, and science has removed inscriptions of social 
characteristics from the diseases themselves. While this demonstrates 
that BioPrivilege’s adaptations do not all succeed, the use of “risk 
groups” now offers space for those characteristics to adapt and 
survive. In the invisible space outside those risk groups, the risk-free 
groups still thrive. 
IV. BIOEQUALITY? 
Wildman & Co. point out that “[s]ubordination will grow back 
from the ignored head of privilege.”72 They identify the necessary 
first step in countering the hydra as seeing and revealing privilege. 
The next step is creating public space for a collective, multi-voiced 
reimagining of community and social justice.
73
 Education offers one 
such space. But others have been forged, even in the sciences. 
Several examples have emerged from biomedicine. More 
accurately, challenges to subordination and privilege in biomedicine 
have produced several projects that take the next step toward 
something like BioEquality. Each may contain limits or face 
challenges that conscribe its potential to make biomedicine so 
inclusive that its benefits accrue to all and its risk of harm is spread 
among those who can bear it. The most obvious challenges involve 
existing limits on access to health care. As obvious is the fact that 
biomedicine is not a silo enterprise, separate and apart from other 
social, political, and economic enterprises. Therefore, any effort 
aimed at erasing BioPrivilege must be one of many. Yet, each 
mentioned here contains a gem. 
A. Revealing Privilege, Requiring Inclusion 
Two projects mentioned above have effected change. Feminist 
and civil rights challenges to the normative white male body 
combined with substantive requirements of inclusion simultaneously 
reveal privilege and curb subordination. 
 
 72. WILDMAN, supra note 1, at 20.  
 73. Id. at 159. 
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Feminist critiques of the normative male body have expanded the 
norm somewhat. The normative body now has more than one 
identity. Female bodies are often included as different but normal and 
thus are less likely to be described as deviant and problematic. Future 
providers and researchers are less likely to encounter gender bias in 
their curricular materials and more likely to acquire sufficient 
knowledge about women’s bodies and health needs.  
As mentioned, health disparities work became federal policy in 
the 1990s and overlapped with critiques of the normative body.
74
 In 
the 1990s, federal policy began to require inclusion of women and 
racial and ethnic minorities in clinical trials, as well as the collection 
of race- and ethnic-specific data. This work has expanded the 
biomedical research agenda and the understanding of the nation’s 
health care needs. If implemented vigorously, health disparities 
policy should help reduce significant differences in morbidity and 
mortality rates by sex, race, and ethnicity.  
But both of these projects have internal limits. Health disparities 
work has been limited by its own terms. “Health disparities” work 
typically distances the task of understanding population differences in 
disease and mortality from civil rights work. “Health disparities” 
typically uses an acontextual, data-based approach. This framing 
limits space for identifying and addressing the role of subordination 
and privilege in contributing to or directly causing those differences. 
And yet, many health advocates continue to insist on addressing 
“health disparities” using anti-discrimination and social justice 
approaches. 
In the meantime, the list of normative bodies has remained very 
short. The list still does not include persons with disabilities, persons 
with ambiguous genitalia, transgendered persons who have 
undergone sex-reassignment surgery, and others. 
And the list defaults to male on a regular basis. It is most often 
white. And yet, advocates from many communities are working to fill 
the blank space that follows the very short list. 
 
 74. See supra Part II for a discussion of the normative body. 
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B. Movement Work 
A second type of project uses grassroots organizing to carve out 
space for voices and bodies not previously included in the biomedical 
enterprise. The most successful efforts have directly challenged 
privileging norms. The Women’s Health Movement, started in the 
1970s, and the AIDS movement, formed in the 1980s, have both used 
organizing and self-education to make lay interventions and effect 
change in research agendas, medical care, patient support, and social 
norms.
75
 
The AIDS movement began as a broad-based, diverse 
movement,
76
 while the Women’s Health Movement grew in diversity 
as it evolved.
77
 Both movements have used a wide range of strategies, 
including developing lay research experts, establishing health care 
clinics to provide unbiased care, drafting and promoting legislation, 
and mobilizing public support. Both movements have also reached 
out to a wide range of communities, and both have made global 
impacts. The AIDS movement, in particular, has impacted the way 
science is produced.
78
 Both movements forced biomedicine to 
acknowledge that science does not live in a silo but in the messy 
world of social life and politics.  
But during the past three decades, the economics of biomedicine 
have changed. Biomedicine is now significantly privatized. 
Privatization has repositioned patients as consumers. That economic 
shift occurred as part of a larger political embrace of neoliberalism in 
the United States. Within the neoliberal paradigm, patients are not 
only consumers, but consumers who bear responsibility for their own 
health status, risks, and treatment choices. Healthcare consumerism 
introduces new forms of BioPrivilege, particularly on the consumer 
side.  
 
 75. SHERYL BURT RUZEK, THE WOMEN’S HEALTH MOVEMENT: FEMINIST ALTERNATIVES 
TO MEDICAL CONTROL (1979); EPSTEIN, supra note 68, at 8–9. 
 76. EPSTEIN, supra note 68, at 8. 
 77. JAEL SILLIMAN ET AL., UNDIVIDED RIGHTS: WOMEN OF COLOR ORGANIZE FOR 
REPRODUCTIVE JUSTICE 34–35 (2004). 
 78. Id. at 13. 
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V. CONCLUSION 
BioPrivilege exists because “pure science” is a fiction. Biomedical 
knowledge has normative content and normative force. As a result, 
privilege—and subordination—pervade biomedicine.  
This Essay has used a handful of examples to illustrate that point. 
The use of a singular normative body, research design premised on 
that normative body, and disease models that use social identity to 
exclude and universalize are just a few of many forms of 
BioPrivilege.  
The rapid expansion of biomedical enterprise in the last few 
decades makes revealing BioPrivilege an important duty. The power 
of BioPrivilege rests not only on the scope of the enterprise but also, 
in part, on the status of science. Science, particularly biomedicine, 
has contributed and continues to contribute knowledge and goods that 
have both clear extrinsic and immeasurable intrinsic value. But its 
status as a highly valuable social activity should not shield 
biomedicine from scrutiny or democratic participation.  
This Essay taps into a vigorous discourse formed by feminist 
critiques of science, critical race theory, and science and technology 
studies. Most, but not all, of the existing work targets subordination. 
This Essay focuses on the first step—showing the hydra-headed 
nature of the beast—in the context of biomedicine. 
 
Washington University Open Scholarship
